Well, it has been a month now since the last of the big January derm conferences have concluded and Melafinder had added only a handful of new placements.... Looks like everything, at least more than I expected, now rides on the AAD conference starting tomorrow. I can't see Gulfo having anything concrete to tell us or even a hint of new meaningful information for the earnings call next week. Maybe he picked up some more anecdotal stories .... I've been wrong so far on this company , let's hope I am wrong again.
"Well, it has been a month now since the last of the big January derm conferences have concluded and Melafinder had added only a handful of new placements.."
You're not accounting for the lag time from contract signing to actual placement. I believe that Gulfo said in a recent CC that it was 4 to 6 weeks when he was specifically asked that question. In addition, I don't imagine that a Derm will be listed on the melafinder until he/she gives the OK that they are comfortable with using it.
Several months ago I brought up my belief that there were going to be a certain number of docs who always have to have the "next big thing" who would jump to buy mela but that afterwards, placement would slow radically. The capt said that I was wrong (more like FOS).
Hmmmmmmm...... a long now seeing my point of view. Late and unprofitably so but still..... seeing my point of view.
"Several months ago I brought up my belief that there were going to be a certain number of docs who always have to have the "next big thing" who would jump to buy mela but that afterwards, placement would slow radically. The capt said that I was wrong (more like FOS)."
While I'm am quite sure that you love feeding on anything that a long post in a negative manner about MELA, may I suggest
1) Show me a post where you said anything like that and which I responded to you.
2) Perhaps we should wait and see how well Gulfo meets his goal of 275 by Mar 31.
Just about everything meeting attendees deem important will be on the agenda today at one of the Annual Meeting's most popular sessions, "Hot Topics." Presented from 2 to 5 p.m. in the Fillmore Theater, speakers at the session will discuss cosmeceuticals, contact dermatitis, melanoma, vitamin D, health system reform, drug reactions, and acne.
The loosely structured, interactive session, directed by Kenneth Tomecki, MD, will explore several issues that currently affect and impact the specialty, as chosen by meeting attendees. When people registered to attend Annual Meeting, they were surveyed to find out which topics they wanted to learn more about.
Following is the list of hot topics chosen, and their presenters:
Cosmeceuticals: What Really Works, Zoe Diana Draelos, MD
Contact Dermatitis: What's Bubbling Up, David Eric Cohen, MD
Melanoma Update 2013, Allan C. Halpern, MD
Biologic Therapy: Safety Update 2013, Mark Lebwohl, MD
Controversies in Vitamin D: A Dermatologist's Perspective, Wilma Fowler Bergfeld, MD
Health Care Reform: What's Next, Jack S. Resneck Jr., MD
Drug Reaction Update 2013, J. Mark Jackson, MD
Laser Rx for Onychomycosis: Fact or Fancy, Murad Alam, MD
Acne: What's New, Neal D. Bhatia, MD